Hyaluronic acid-modified cationic nanoparticles overcome enzyme CYP1B1-mediated breast cancer multidrug resistance

被引：18
|
作者：
Zhang, Jun [1 ]
Song, Jia [1 ]
Liang, Xiao [1 ]
Yin, Yunzhi [1 ]
Zuo, Tiantian [1 ]
Chen, Daijie [1 ]
Shen, Qi [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Pharm, 800 Dongchuan Rd, Shanghai 200240, Peoples R China
来源：
NANOMEDICINE | 2019年 / 14卷 / 04期
关键词：
alpha-napthtoflavone; breast cancer; CD44; CYP1B1; DTX; hyaluronic acid; lysosome escape; multidrug resistance; nanoparticles; polyethyleneimine; MESOPOROUS SILICA; ANTICANCER DRUGS; DELIVERY; DOCETAXEL; MICELLES; CYP1B1; CYTOCHROME-P450; PACLITAXEL; CELLS; FORMULATIONS;
D O I：
10.2217/nnm-2018-0244
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Aim: Enzyme CYP1B1 (CYP1B1) is usually overexpressed in multidrug resistance (MDR) breast cancer cells, which could metabolically inactivate docetaxel (DTX). Materials & methods: The cationic core-shell nanoparticles (hyaluronic acid/polyethyleneimine nanoparticles[HA/PEI NPs]) modified with hyaluronic acid (HA) were developed and coloaded with DTX and alpha-napthtoflavone (ANF, a CYP1B1 inhibitor) to overcome MDR in breast cancer induced by CYP1B1. Physicochemical characterization, MDR reversing effect in vitro and pharmacokinetics in vivo of HA/PEI NPs were evaluated. Results: The HA/PEI NPs exhibited spherical morphology with size of (193.6 +/- 3.1) nm. The HA/PEI NPs could reverse MDR effectively by downregulating the expression of CYP1B1. The HA/PEI NPs improved the bioavailability of DTX. Conclusion:The HA/PEI NPs might be a promising strategy to overcome CYP1B1-mediated breast cancer MDR. [GRAPHICS]
引用
收藏
页码：447 / 464
页数：18
相关论文
共 50 条
  • [21] Nicotine-mediated suppression of the retinoic acid metabolizing enzyme CYP26A1 limits the oncogenic potential of breast cancer
    Osanai, Makoto
    Lee, Gang-Hong
    CANCER SCIENCE, 2011, 102 (06) : 1158 - 1163
  • [22] Application of a CYP1B1-Targeted NIR Probe for Breast Cancer Diagnosis, Surgical Navigation, and CYP1B1-Associated Chemotherapy Resistance Monitoring
    Wu, Zhihao
    Shi, Tao
    Shao, Qi
    Chen, Dongmei
    Gao, Peisheng
    Wang, Jie
    Xu, Ting
    Meng, Qingqing
    Li, Shaoshun
    MOLECULAR PHARMACEUTICS, 2025, 22 (03) : 1507 - 1517
  • [23] Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted PLK1 siRNAs for treating bladder cancer
    Shahidi, Maryamsadat
    Abazari, Omid
    Dayati, Parisa
    Reza, Javad Zavar
    Modarressi, Mohammad Hossein
    Tofighi, Davood
    Haghiralsadat, Bibi Fatemeh
    Oroojalian, Fatemeh
    NANOMEDICINE, 2023, 18 (03) : 259 - 277
  • [24] Preparation, Evaluation, and Bioinformatics Study of Hyaluronic Acid-Modified Ginsenoside Rb1 Self-Assembled Nanoparticles for Treating Cardiovascular Diseases
    Du, Lixin
    Xiao, Yifei
    Wei, Qidong
    Guo, Zhihua
    Li, Ya
    MOLECULES, 2024, 29 (18):
  • [25] Targeting HSP90AA1 to overcome multiple drug resistance in breast cancer using magnetic nanoparticles loaded with salicylic acid
    Chen, Ou
    Fu, Linlin
    Wang, Yu
    Li, Jinggui
    Liu, Jun
    Wen, Yanqing
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2025, 298
  • [26] Cationic anticancer peptide L-K6-modified and doxorubicin-loaded mesoporous silica nanoparticles reverse multidrug resistance of breast cancer
    Sun, Haiting
    Dong, Shaodan
    Kong, Lingying
    Wang, Rongchun
    Zhao, Jiaqi
    Guan, Yue
    Wang, Che
    Shang, Dejing
    ARABIAN JOURNAL OF CHEMISTRY, 2024, 17 (05)
  • [27] Development of hyaluronic acid–anchored polycaprolactone nanoparticles for efficient delivery of PLK1 siRNA to breast cancer
    Dolly Jain
    Awesh K. Yadav
    Drug Delivery and Translational Research, 2023, 13 : 1730 - 1744
  • [28] EGFR-mediated G1/S transition contributes to the multidrug resistance in breast cancer cells
    Shu-Jun Chen
    Jing Luan
    Hai-Shi Zhang
    Can-Ping Ruan
    Xin-Yun Xu
    Qing-Quan Li
    Nian-Hong Wang
    Molecular Biology Reports, 2012, 39 : 5465 - 5471
  • [29] EGFR-mediated G1/S transition contributes to the multidrug resistance in breast cancer cells
    Chen, Shu-Jun
    Luan, Jing
    Zhang, Hai-Shi
    Ruan, Can-Ping
    Xu, Xin-Yun
    Li, Qing-Quan
    Wang, Nian-Hong
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (05) : 5465 - 5471
  • [30] Folic acid-modified disulfiram/Zn-IRMOF3 nanoparticles for oral cancer therapy by inhibiting ALDH1A1+cancer stem cells
    Cui, Jiasen
    Li, Weitao
    Bu, Wenhuan
    Liu, Jinhui
    Chen, Xi
    Li, Xuewen
    Liu, Chunran
    Meng, Lin
    Chen, Mingli
    Sun, Hongchen
    Wang, Jianhua
    BIOMATERIALS ADVANCES, 2022, 139
12345